Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-	341.3	249.7	154.5	89.6
Depreciation & Amortization	-	27.1	21.3	15.6	10.9
Other Amortization	-	-	-	-	17.3
Loss (Gain) From Sale of Investments	-	10.9	-46.7	-27.1	-13.5
Stock-Based Compensation	-	195.5	194.3	173.1	134.2
Other Operating Activities	-	39.8	-56.9	90.7	1.3
Change in Accounts Receivable	-	-39.8	-89.3	-162.2	-28.4
Change in Inventory	-	-19.1	5.4	-2.6	-2.5
Change in Accounts Payable	-	29	64.3	114.6	56.8
Change in Other Net Operating Assets	-	10.7	47.8	-17.2	-9.2
Operating Cash Flow	-	595.4	389.9	339.4	256.5
Operating Cash Flow Growth	-	52.71%	14.88%	32.32%	12.25%
Capital Expenditures	-	-38.2	-28.3	-16.5	-23.4
Cash Acquisitions	-	-	-	-42.7	-
Investment in Securities	-	-88.6	-438.8	-117.9	-106.8
Investing Cash Flow	-	-126.8	-467.1	-177.1	-130.2
Long-Term Debt Repaid	-	-308.8	-	-279	-0.1
Net Debt Issued (Repaid)	-	-308.8	-	-279	-0.1
Issuance of Common Stock	-	122.1	65.3	44.7	27.5
Repurchase of Common Stock	-	-300	-	-	-
Financing Cash Flow	-	-486.7	65.3	-234.3	27.4
Foreign Exchange Rate Adjustments	-	-	0.3	-1.3	-
Net Cash Flow	-	-18.1	-11.6	-73.3	153.7
Free Cash Flow	-	557.2	361.6	322.9	233.1
Free Cash Flow Growth	-	54.09%	11.98%	38.52%	7.12%
Free Cash Flow Margin	-	23.66%	19.16%	21.69%	20.57%
Free Cash Flow Per Share	-	5.37	3.58	3.27	2.38
Cash Interest Paid	-	1.6	3.8	6.6	8.6
Cash Income Tax Paid	-	217.5	51.5	14.4	5.1
Levered Free Cash Flow	-	457.98	439.25	247.63	265.75
Unlevered Free Cash Flow	-	457.98	439.25	247.63	264.58
Change in Working Capital	-	-19.2	28.2	-67.4	16.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.